Temi della conferenza As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more
